We are upgrading the repository! A content freeze is in effect until December 6, 2024. New submissions or changes to existing items will not be allowed during this period. All content already published will remain publicly available for searching and downloading. Updates will be posted in the Website Upgrade 2024 FAQ in the sidebar Help menu. Reach out to escholarship@umassmed.edu with any questions.
Challenges and solutions to superior chimeric antigen receptor-T design and deployment for B-cell lymphomas
Student Authors
Jenny GaoUMass Chan Affiliations
MedicineMorningside Graduate School of Biomedical Sciences
RNA Therapeutics Institute
Document Type
Journal ArticlePublication Date
2023-07-24
Metadata
Show full item recordAbstract
Chimeric antigen receptor-T (CAR-T) therapies represent a major breakthrough in cancer medicine, given the ex vivo-based technology that harnesses the power of one's own immune system. These therapeutics have demonstrated remarkable success for relapsed/refractory B-cell lymphomas. Although more than a decade has passed since the initial introduction of CAR-T therapeutics for patients with leukaemia and lymphoma, there is still significant debate as to where CAR-T therapeutics fit into the management paradigm, as consensus guidelines are limited. Competing interventions deployed in subsequent lines of therapy for aggressive lymphoma include novel targeted agents, bispecific antibodies, and time-honoured stem cell transplant. In this focused review, we discuss the major obstacles to advancing the therapeutic reach for CAR-T products in early lines of therapy. Such barriers include antigen escape, "cold" tumour microenvironments, host inflammation and CAR-T cell exhaustion. We highlight solutions including point-of-care CAR-T manufacturing and early T lymphopheresis. We review the evidence basis for early CAR-T deployment for B-cell lymphomas in light of the recent Food and Drug Administration (FDA) approval of three first-in-class anti-CD3/CD20 bispecific antibodies-mosunetuzumab, epcoritamab and glofitamab. We propose practical recommendations for 2024.Source
Gao J, Dahiya S, Patel SA. Challenges and solutions to superior chimeric antigen receptor-T design and deployment for B-cell lymphomas. Br J Haematol. 2023 Oct;203(2):161-168. doi: 10.1111/bjh.19001. Epub 2023 Jul 24. PMID: 37488074.DOI
10.1111/bjh.19001Permanent Link to this Item
http://hdl.handle.net/20.500.14038/52689PubMed ID
37488074Funding and Acknowledgements
UMass Center for Clinical and Translational Science. Grant Number: UL1TR001453Rights
© 2023 British Society for Haematology and John Wiley & Sons Ltd.ae974a485f413a2113503eed53cd6c53
10.1111/bjh.19001